Legal & General Group PLC Cor Medix Inc. Transaction History

Legal & General Group PLC

$440 Billion
Q2 2024

A detailed history of Legal & General Group PLC transactions in Cor Medix Inc. stock. As of the latest transaction made, Legal & General Group PLC holds 6,151 shares of CRMD stock, worth $49,515. This represents 0.0% of its overall portfolio holdings.

Number of Shares

6,151

Previous 5,920 3.9%

Holding current value

$49,515

Previous $25,000 4.0%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$4.08 - $6.39 $942 - $1,476	231 Added 3.9%	6,151 $26,000
Q1 2024 May 14, 2024	SELL	$2.94 - $4.24 $752 - $1,085	-256 Reduced 4.15%	5,920 $25,000
Q4 2023 Feb 15, 2024	BUY	$3.0 - $4.01 $1,818 - $2,430	606 Added 10.88%	6,176 $23,000
Q3 2023 Nov 14, 2023	BUY	$3.6 - $4.46 $907 - $1,123	252 Added 4.74%	5,570 $20,000
Q2 2023 Aug 14, 2023	BUY	$3.94 - $5.8 $20,952 - $30,844	5,318 New	5,318 $21,000
Q2 2022 Aug 22, 2022	SELL	$2.73 - $5.61 $8,736 - $17,952	-3,200 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$4.46 - $7.11 $1,052 - $1,677	-236 Reduced 6.87%	3,200 $15,000
Q2 2021 Aug 12, 2021	SELL	$6.05 - $10.09 $1,718 - $2,865	-284 Reduced 7.63%	3,436 $24,000
Q3 2020 Nov 13, 2020	SELL	$3.96 - $6.15 $978 - $1,519	-247 Reduced 6.23%	3,720 $22,000
Q1 2020 May 14, 2020	SELL	$2.35 - $7.08 $2,009 - $6,053	-855 Reduced 17.73%	3,967 $14,000
Q4 2019 Feb 13, 2020	BUY	$4.96 - $7.75 $4,399 - $6,874	887 Added 22.54%	4,822 $33,000
Q2 2019 Aug 14, 2019	BUY	$5.93 - $10.57 $23,334 - $41,592	3,935 New	3,935 $30,000

Others Institutions Holding CRMD

# of Institutions

101

Shares Held

16.9M

Call Options Held

70.5K

Put Options Held

358K

View Full List

About CorMedix Inc.

Ticker CRMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 41,208,200
Market Cap $332M
Description
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its lead product candidate is DefenCath/Neutrolin, a novel anti-infective solution for the reduction and prevention of cathet...

More about CRMD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Legal & General Group PLC with notifications on news.

Account

Legal & General Group PLC Cor Medix Inc. Transaction History